论文部分内容阅读
目的：探讨布地奈德福莫特罗联合苏黄止咳胶囊对咳嗽变异性哮喘( CVA)的疗效。方法选择2014年08月—2015年12月遂宁市中心医院呼吸内科门诊诊断的CVA患者98例,并将其随机分为A组33例、B 组33例和C 组32例。 A 组患者给予布地奈德福莫特罗联合苏黄止咳胶囊治疗,B 组患者给予布地奈德福莫特罗治疗,C 组患者给予苏黄止咳胶囊治疗,疗程28天。比较治疗前、治疗后入组患者咳嗽症状、肺功能、炎症因子的变化。结果治疗前3组患者咳嗽症状、肺功能、炎症因子比较,差异无统计学意义( P>0．05)。治疗28天后,B组和C组患者咳嗽评分、炎症因子IL-4、IL-5、TNF-α高于A组(P<0．05),肺功能提示A组支气管激发试验或舒张试验阴转率明显高于B、C组(P0. 05). After 28-day treatment, cough score, inflammatory factor IL-4, IL-5 and TNF-α in the group B and C were higher than those in the group A (P<0. 05). Meanwhile, pulmonary function data suggested that the negative transfer rate of bronchial provocation test or diastolic test in the group A were significantly higher than that in the group B and C (P<0. 05). Conclusion Budesonide/fomoterol combined with Suhuang cough capsule is more ef-fective than budesonide/fomoterol or Suhuang cough capsule separately in improving the cough symptoms in CVA. Meanwhile, the combination can improve lung function and decrease the levels of inflammatory factors. At last, we suggest that the level of inflammatory factors is associated with the improvement of cough symptoms and lung function.